Company’s 36-month beta value is 1.82.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy”, 1 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for VYNE is 13.63M, and currently, short sellers hold a 2.53% ratio of that floaft. The average trading volume of VYNE on July 08, 2025 was 572.04K shares.
VYNE stock’s latest price update
VYNE Therapeutics Inc (NASDAQ: VYNE) has experienced a decline in its stock price by -9.47% compared to its previous closing price of $1.42. However, the company has seen a fall of -9.15% in its stock price over the last five trading days. globenewswire.com reported 2025-07-02 that BRIDGEWATER, N.J., July 02, 2025 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today provided a program update for VYN202 following the clinical hold issued by the U.S. Food and Drug Administration (FDA) in April for the Company’s Phase 1b clinical trial in the treatment of moderate-to-severe plaque psoriasis. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immune-mediated diseases.
VYNE’s Market Performance
VYNE Therapeutics Inc (VYNE) has seen a -9.15% fall in stock performance for the week, with a 30.30% gain in the past month and a -22.75% plunge in the past quarter. The volatility ratio for the week is 17.25%, and the volatility levels for the past 30 days are at 13.85% for VYNE. The simple moving average for the past 20 days is 10.64% for VYNE’s stock, with a -38.64% simple moving average for the past 200 days.
Analysts’ Opinion of VYNE
Many brokerage firms have already submitted their reports for VYNE stocks, with BTIG Research repeating the rating for VYNE by listing it as a “Buy”. The predicted price for VYNE in the upcoming period, according to BTIG Research is $8 based on the research report published on November 18, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see VYNE reach a price target of $7. The rating they have provided for VYNE stocks is “Buy” according to the report published on December 06th, 2021.
VYNE Trading at 7.90% from the 50-Day Moving Average
After a stumble in the market that brought VYNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.00% of loss for the given period.
Volatility was left at 13.85%, however, over the last 30 days, the volatility rate increased by 17.25%, as shares surge +29.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.89% lower at present.
During the last 5 trading sessions, VYNE fell by -9.15%, which changed the moving average for the period of 200-days by -31.38% in comparison to the 20-day moving average, which settled at $1.1660. In addition, VYNE Therapeutics Inc saw -28.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VYNE starting from LEPORE PATRICK G, who purchase 15,000 shares at the price of $2.92 back on Jan 15 ’25. After this action, LEPORE PATRICK G now owns 51,472 shares of VYNE Therapeutics Inc, valued at $43,800 using the latest closing price.
N/A, the N/A of VYNE Therapeutics Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for VYNE
Current profitability levels for the company are sitting at:
- -74.15% for the present operating margin
- 0.66% for the gross margin
The net margin for VYNE Therapeutics Inc stands at -69.73%. The total capital return value is set at -1.02%. Equity return is now at value -66.15%, with -56.95% for asset returns.
Based on VYNE Therapeutics Inc (VYNE), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -594.46.
Currently, EBITDA for the company is -43.63 million with net debt to EBITDA at 0.64. When we switch over and look at the enterprise to sales, we see a ratio of -10.99. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.47.
Conclusion
In a nutshell, VYNE Therapeutics Inc (VYNE) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
